The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
Pancreatic ductal adenocarcinoma (PDAC) is still difficult to treat due to insufficient methods for early diagnosis and prediction of therapy response. Furthermore, surveillance after curatively intended surgery lacks adequate methods for timely detection of recurrence. Therefore, several molecules...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-01, Vol.14 (1), p.217 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 217 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Sturm, Niklas Ettrich, Thomas J Perkhofer, Lukas |
| description | Pancreatic ductal adenocarcinoma (PDAC) is still difficult to treat due to insufficient methods for early diagnosis and prediction of therapy response. Furthermore, surveillance after curatively intended surgery lacks adequate methods for timely detection of recurrence. Therefore, several molecules have been analyzed as predictors of recurrence or early detection of PDAC. Enhanced understanding of molecular tumorigenesis and treatment response triggered the identification of novel biomarkers as predictors for response to conventional chemotherapy or targeted therapy. In conclusion, progress has been made especially in the prediction of therapy response with biomarkers. The use of molecules for early detection and recurrence of PDAC is still at an early stage, but there are promising approaches in noninvasive biomarkers, composite panels and scores that can already ameliorate the current clinical practice. The present review summarizes the current state of research on biomarkers for diagnosis and therapy of pancreatic cancer. |
| doi_str_mv | 10.3390/cancers14010217 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8750069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2618909027</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-b0abef870a96a2b0cb415332b48a12469e9b5baecb67e1fc064d4d45374d4cba3</originalsourceid><addsrcrecordid>eNpdkUtLAzEUhYMoKtW1Owm4cWFtHtNkZiP4tlBQUNfhJs3Y1GlSkxnBf2-qVaoJJIF89-SeHIQOKDnlvCIDA97YmGhBKGFUbqBdRiTrC1EVm2vnHbSf0ozkwTmVQm6jHT4kpOQl3UXmaWrxaL4A0-JQ4wsX5hBfsyp2Hj_kB6KF1hl81ZkWGnw-sT4YiMb5DOLg8ZWDFx-SSyf4sYvv1jXNsi0MfoKzdoTFxx7aqqFJdn-199DzzfXT5V1_fH87ujwf903BaNvXBLStS0mgEsA0MbqgQ86ZLkqgrBCVrfRQgzVaSEtrQ0QxyXPIZV6NBt5DZ9-6i07P7cRY30Zo1CK67OlDBXDq7413U_US3lUp83-IKgscrwRieOtsatXcJWOXjmzokmKClhWpCJMZPfqHzkIXfbb3RTFSUs4zNfimTAwpRVv_NkOJWmao_mWYKw7XPfzyP4nxTwZfmfM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618208133</pqid></control><display><type>article</type><title>The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Sturm, Niklas ; Ettrich, Thomas J ; Perkhofer, Lukas</creator><creatorcontrib>Sturm, Niklas ; Ettrich, Thomas J ; Perkhofer, Lukas</creatorcontrib><description>Pancreatic ductal adenocarcinoma (PDAC) is still difficult to treat due to insufficient methods for early diagnosis and prediction of therapy response. Furthermore, surveillance after curatively intended surgery lacks adequate methods for timely detection of recurrence. Therefore, several molecules have been analyzed as predictors of recurrence or early detection of PDAC. Enhanced understanding of molecular tumorigenesis and treatment response triggered the identification of novel biomarkers as predictors for response to conventional chemotherapy or targeted therapy. In conclusion, progress has been made especially in the prediction of therapy response with biomarkers. The use of molecules for early detection and recurrence of PDAC is still at an early stage, but there are promising approaches in noninvasive biomarkers, composite panels and scores that can already ameliorate the current clinical practice. The present review summarizes the current state of research on biomarkers for diagnosis and therapy of pancreatic cancer.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14010217</identifier><identifier>PMID: 35008381</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adenocarcinoma ; Antigens ; Biomarkers ; Cancer therapies ; Carbohydrates ; Chemotherapy ; Diagnosis ; Medical prognosis ; Metabolism ; Metabolites ; Metastases ; Pancreatic cancer ; Pancreatitis ; Patients ; Review ; Saliva ; Surveillance ; Tumorigenesis ; Urine</subject><ispartof>Cancers, 2022-01, Vol.14 (1), p.217</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-b0abef870a96a2b0cb415332b48a12469e9b5baecb67e1fc064d4d45374d4cba3</citedby><cites>FETCH-LOGICAL-c421t-b0abef870a96a2b0cb415332b48a12469e9b5baecb67e1fc064d4d45374d4cba3</cites><orcidid>0000-0002-7654-2442 ; 0000-0003-0484-0974</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750069/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750069/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35008381$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sturm, Niklas</creatorcontrib><creatorcontrib>Ettrich, Thomas J</creatorcontrib><creatorcontrib>Perkhofer, Lukas</creatorcontrib><title>The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Pancreatic ductal adenocarcinoma (PDAC) is still difficult to treat due to insufficient methods for early diagnosis and prediction of therapy response. Furthermore, surveillance after curatively intended surgery lacks adequate methods for timely detection of recurrence. Therefore, several molecules have been analyzed as predictors of recurrence or early detection of PDAC. Enhanced understanding of molecular tumorigenesis and treatment response triggered the identification of novel biomarkers as predictors for response to conventional chemotherapy or targeted therapy. In conclusion, progress has been made especially in the prediction of therapy response with biomarkers. The use of molecules for early detection and recurrence of PDAC is still at an early stage, but there are promising approaches in noninvasive biomarkers, composite panels and scores that can already ameliorate the current clinical practice. The present review summarizes the current state of research on biomarkers for diagnosis and therapy of pancreatic cancer.</description><subject>Adenocarcinoma</subject><subject>Antigens</subject><subject>Biomarkers</subject><subject>Cancer therapies</subject><subject>Carbohydrates</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Medical prognosis</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metastases</subject><subject>Pancreatic cancer</subject><subject>Pancreatitis</subject><subject>Patients</subject><subject>Review</subject><subject>Saliva</subject><subject>Surveillance</subject><subject>Tumorigenesis</subject><subject>Urine</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkUtLAzEUhYMoKtW1Owm4cWFtHtNkZiP4tlBQUNfhJs3Y1GlSkxnBf2-qVaoJJIF89-SeHIQOKDnlvCIDA97YmGhBKGFUbqBdRiTrC1EVm2vnHbSf0ozkwTmVQm6jHT4kpOQl3UXmaWrxaL4A0-JQ4wsX5hBfsyp2Hj_kB6KF1hl81ZkWGnw-sT4YiMb5DOLg8ZWDFx-SSyf4sYvv1jXNsi0MfoKzdoTFxx7aqqFJdn-199DzzfXT5V1_fH87ujwf903BaNvXBLStS0mgEsA0MbqgQ86ZLkqgrBCVrfRQgzVaSEtrQ0QxyXPIZV6NBt5DZ9-6i07P7cRY30Zo1CK67OlDBXDq7413U_US3lUp83-IKgscrwRieOtsatXcJWOXjmzokmKClhWpCJMZPfqHzkIXfbb3RTFSUs4zNfimTAwpRVv_NkOJWmao_mWYKw7XPfzyP4nxTwZfmfM</recordid><startdate>20220103</startdate><enddate>20220103</enddate><creator>Sturm, Niklas</creator><creator>Ettrich, Thomas J</creator><creator>Perkhofer, Lukas</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7654-2442</orcidid><orcidid>https://orcid.org/0000-0003-0484-0974</orcidid></search><sort><creationdate>20220103</creationdate><title>The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy</title><author>Sturm, Niklas ; Ettrich, Thomas J ; Perkhofer, Lukas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-b0abef870a96a2b0cb415332b48a12469e9b5baecb67e1fc064d4d45374d4cba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adenocarcinoma</topic><topic>Antigens</topic><topic>Biomarkers</topic><topic>Cancer therapies</topic><topic>Carbohydrates</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Medical prognosis</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metastases</topic><topic>Pancreatic cancer</topic><topic>Pancreatitis</topic><topic>Patients</topic><topic>Review</topic><topic>Saliva</topic><topic>Surveillance</topic><topic>Tumorigenesis</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sturm, Niklas</creatorcontrib><creatorcontrib>Ettrich, Thomas J</creatorcontrib><creatorcontrib>Perkhofer, Lukas</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sturm, Niklas</au><au>Ettrich, Thomas J</au><au>Perkhofer, Lukas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-01-03</date><risdate>2022</risdate><volume>14</volume><issue>1</issue><spage>217</spage><pages>217-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Pancreatic ductal adenocarcinoma (PDAC) is still difficult to treat due to insufficient methods for early diagnosis and prediction of therapy response. Furthermore, surveillance after curatively intended surgery lacks adequate methods for timely detection of recurrence. Therefore, several molecules have been analyzed as predictors of recurrence or early detection of PDAC. Enhanced understanding of molecular tumorigenesis and treatment response triggered the identification of novel biomarkers as predictors for response to conventional chemotherapy or targeted therapy. In conclusion, progress has been made especially in the prediction of therapy response with biomarkers. The use of molecules for early detection and recurrence of PDAC is still at an early stage, but there are promising approaches in noninvasive biomarkers, composite panels and scores that can already ameliorate the current clinical practice. The present review summarizes the current state of research on biomarkers for diagnosis and therapy of pancreatic cancer.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35008381</pmid><doi>10.3390/cancers14010217</doi><orcidid>https://orcid.org/0000-0002-7654-2442</orcidid><orcidid>https://orcid.org/0000-0003-0484-0974</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-01, Vol.14 (1), p.217 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8750069 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Adenocarcinoma Antigens Biomarkers Cancer therapies Carbohydrates Chemotherapy Diagnosis Medical prognosis Metabolism Metabolites Metastases Pancreatic cancer Pancreatitis Patients Review Saliva Surveillance Tumorigenesis Urine |
| title | The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T22%3A40%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20Biomarkers%20in%20Pancreatic%20Ductal%20Adenocarcinoma%20on%20Diagnosis,%20Surveillance%20and%20Therapy&rft.jtitle=Cancers&rft.au=Sturm,%20Niklas&rft.date=2022-01-03&rft.volume=14&rft.issue=1&rft.spage=217&rft.pages=217-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14010217&rft_dat=%3Cproquest_pubme%3E2618909027%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2618208133&rft_id=info:pmid/35008381&rfr_iscdi=true |